A Population Based Study Assessing Clinical Outcomes Following Androgen Receptor Axis Therapies (ARAT) among Men with Prostate Cancer (PCa) having Major Cardiovascular Diseases (CVDs) or Extreme Polypharmacy (EPP)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Enzalutamide (Primary)
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

03 Apr 2019 Results assessing the clinical outcomes among patients treated with abiraterone acetate for advanced prostate cancer with pre-existing cardiovascular conditions (n=2,845) presented at the 110th Annual Meeting of the American Association for Cancer Research
30 Jun 2018 New trial record
05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight